Characterization of the broad-spectrum antibacterial activity of bacteriocin-like inhibitory substance-producing probiotics isolated from fermented foods

Bacteriocin, produced by probiotics, has potential as a therapeutic agent for treating infectious diseases. Studies on fermented foods’ lactic acid bacteria (LAB) showed that six strains maintained high viability, produced high exopolysaccharides, and showed no cytotoxicity. Three strains, Weissella confusa CYLB30, Lactiplantibacillus plantarum CYLB47, and Limosilactobacillus fermentum CYLB55, demonstrated strong antibacterial effects against drug-resistant bacteria. The bacteriocin gene cluster was found in the CYLB47 genome, suggesting CYLB30 and CYLB47 BLIS as potential treatments for multidrug-resistant bacteria infections.